Please assess the completion status of the following clinical trial:

Trial Title: RAD001 Plus Bevacizumab in Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed melanoma.~2. Unresectable stage IV disease, or recurrent disease with metastases.~3. Measurable disease (by Response Evaluation Criteria in Solid Tumors \[RECIST\]) or measurable skin lesions.~4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.~5. Life expectancy \>=12 weeks.~6. Patients are allowed 0-2 prior treatment regimens containing chemotherapy and/or immunotherapy (interferon, interleukin 2).~7. Women of childbearing potential must have a negative serum pregnancy test with 7 days before beginning treatment.~8. Absolute neutrophil count (ANC) \>=1500/µL, and platelets \>=100,000/µL.~9. Serum creatinine \<=2.0 mg/dL.~10. Serum bilirubin \<=1.5 mg/dL institutional upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<2.5 × ULN or \<5 × ULN in patients with documented liver metastases.~Exclusion Criteria:~1. Previous treatment with bevacizumab or other anti-angiogenesis agents.~2. Previous treatment with mTOR inhibitors.~3. Drugs or substances known to be inhibitors or inducers of the isoenzyme CYP3A are not allowed.~4. Treatment with investigational agents within 4 weeks of study entry.~5. Treatment with more than two previous chemotherapy regimens.~6. Immunization with attenuated live vaccines within one week of study or anytime during study treatment period.~7. Female patients who are pregnant or breastfeeding.~8. Central nervous system (CNS) involvement by metastatic melanoma.~9. CNS disease (e.g., seizures not controlled with standard medical therapy, history of stroke).~10. Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study such as:~    * Severely impaired lung function.~   * Uncontrolled diabetes as defined by fasting serum glucose \>1.5 ULN,~   * Any acute or chronic uncontrolled infection/disorder.~   * Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardize by the treatment with the study therapy.~   * Any acute or chronic uncontrolled infection/disorder.~   * Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardize by the treatment with the study therapy.~   * Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.~11. Acute myocardial infarction (MI) with the previous 6 months.~12. Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, New York Heart Association \[NYHA\] Class II or greater congestive heart failure \[CHF\], serious cardiac arrhythmia requiring medication), or \>= grade 2 vascular disease.~13. Clinical history of hemoptysis or hematemesis.~14. Clinical evidence or history of a bleeding diathesis or coagulopathy.~15. Major surgical procedures, fine-needle aspirations, or core biopsies with 7 days of starting treatment.~16. Patients with PEG tubes or G-tubes.~17. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).~18. Proteinuria at screening as demonstrated by either~    1. Urine protein:creatinine (UPC) ratio \>= 1.0 at screening OR~   2. Urine dipstick for proteinuria \>= 2+ (patients discovered to have \>=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate \<= 1g of protein in 24 hours to be eligible).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).